Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
Authors
Lassen, UChinot, O
McBain, Catherine A
Mau-Sørensen, M
Larsen, V
Barrie, M
Roth, P
Krieter, O
Wang, K
Habben, K
Tessier, J
Lahr, A
Weller, M
Affiliation
Department of Oncology, Rigshospitalet, Copenhagen, DenmarkIssue Date
2015-02-09
Metadata
Show full item recordAbstract
We conducted a phase 1 dose-escalation study of RO5323441, a novel antiplacental growth factor (PlGF) monoclonal antibody, to establish the recommended dose for use with bevacizumab and to investigate the pharmacokinetics, pharmacodynamics, safety/tolerability, and preliminary clinical efficacy of the combination.Citation
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. 2015: Neuro-oncologyJournal
Neuro-oncologyDOI
10.1093/neuonc/nov019PubMed ID
25665807Type
ArticleLanguage
enISSN
1523-5866ae974a485f413a2113503eed53cd6c53
10.1093/neuonc/nov019